Rapydan Topical Anaesthesia for Arterial Cannulation

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

October 31, 2011

Conditions
Arterial Catheterization
Interventions
DRUG

Lidocaine/tetracaine patch

The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.

DRUG

Placebo Patch

A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.

DRUG

Subcutaneous injection of 0.5 ml Lidocain 1%

After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.

DRUG

Subcutaneous injection of saline

After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.

Trial Locations (3)

44195

Cleveland Clinic Department of Outcomes Research, Cleveland

Unknown

Medical University of Vienna, Vienna

Population Health Research Institute, McMaster University, Hamilton

Sponsors
All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

Population Health Research Institute

OTHER

lead

Medical University of Vienna

OTHER

NCT01494311 - Rapydan Topical Anaesthesia for Arterial Cannulation | Biotech Hunter | Biotech Hunter